Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease

Experimental Neurology

Volumn 248, Issue , 2013, Pages 236-245

  Prinz, Alexander ^a   Selesnew, Lisa Marie ^a   Liss, Birgit ^b   Roeper, Jochen ^a   Carlsson, Thomas ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

5 HT; 6 Hydroxydopamine; Electrophysiology; In vitro; Patch clamp; PD

Indexed keywords

3 AMINO 2 (3 CARBOXYPROPYL) 6 (4 METHOXYPHENYL)PYRIDAZINIUM BROMIDE; LEVODOPA; OXIDOPAMINE; SEROTONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DRUG EFFICACY; DRUG MECHANISM; DYSKINESIA; ELECTROENCEPHALOGRAM; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE CELL EXCITABILITY; NERVE CELL PLASTICITY; NONHUMAN; PARKINSON DISEASE; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN FUNCTION; TREATMENT RESPONSE; WAVEFORM;

5-HT; 6-HYDROXYDOPAMINE; ELECTROPHYSIOLOGY; IN VITRO; PATCH-CLAMP; PD;

ANIMALS; ANTIPARKINSON AGENTS; LEVODOPA; MALE; MICE; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RAPHE NUCLEI; SEROTONERGIC NEURONS; SEROTONIN;

EID: 84880378952     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.06.015     Document Type: Article

References (49)

1. Aghajanian G.K., Vandermaelen C.P. Intracellular identification of central noradrenergic and serotonergic neurons by a new double labeling procedure. J. Neurosci. 1982, 2(12):1786-1792.
2. Alvarez-Fischer D., Henze C., Strenzke C., Westrich J., Ferger B., Höglinger G.U., Oertel W.H., Hartmann A. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp. Neurol. 2008, 210(1):182-193.
3. Arai R., Karasawa N., Geffard M., Nagatsu T., Nagatsu I. Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous l-DOPA in the rat, with reference to the involvement of aromatic l-amino acid decarboxylase. Brain Res. 1994, 667(2):295-299.
4. Arai R., Karasawa N., Geffard M., Nagatsu I. l-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci. Lett. 1995, 195(3):195-198.
5. Arai R., Karasawa N., Nagatsu I. Aromatic l-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat A double-labeling immunofluorescence study. Brain Res. 1996, 706(1):177-179.
6. Beck S.G., Pan Y.Z., Akanwa A.C., Kirby L.G. Median and dorsal raphe neurons are not electrophysiologically identical. J. Neurophysiol. 2004, 91(2):994-1005.
7. Bezard E., Tronci E., Pioli E.Y., Li Q., Porras G., Björklund A., Carta M. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov. Disord. 2013, 2013. 10.1002/mds.25366.
8. Bonifati V., Fabrizio E., Cipriani R., Vanacore N., Meco G. Buspirone in levodopa-induced dyskinesias. Clin. Neuropharmacol. 1994, 17(1):73-82. (Feb).
9. Brambilla D., Franciosi S., Opp M.R., Imeri L. Interleukin-1 inhibits firing of serotonergic neurons in the dorsal raphe nucleus and enhances GABAergic inhibitory post-synaptic potentials. Eur. J. Neurosci. 2007, 26(7):1862-1869.
10. Calizo L.H., Akanwa A., Ma X., Pan Y.Z., Lemos J.C., Craige C., Heemstra L.A., Beck S.G. Raphe serotonin neurons are not homogenous: electrophysiological, morphological and neurochemical evidence. Neuropharmacology 2011, 61(3):524-543.
11. Carlsson T., Carta M., Winkler C., Björklund A., Kirik D. Serotonin neuron transplants exacerbate l-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J. Neurosci. 2007, 27(30):8011-8022.
12. Carta M., Carlsson T., Kirik D., Björklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in Parkinsonian rats. Brain 2007, 130(Pt 7):1819-1833.
13. Chu Y.X., Liu J., Feng J., Wang Y., Zhang Q.J., Li Q. Changes of discharge rate and pattern of 5-hydroxytrypamine neurons of dorsal raphe nucleus in a rat model of Parkinson's disease. Sheng Li Xue Bao 2004, 56(5):597-602.
14. de la Fuente-Fernández R., Sossi V., Huang Z., Furtado S., Lu J.Q., Calne D.B., Ruth T.J., Stoessl A.J. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004, 127(Pt 12):2747-2754.
15. Di Giovanni G., Di Matteo V., Pierucci M., Esposito E. Serotonin-dopamine interaction: electrophysiological evidence. Prog. Brain Res. 2008, 172:45-71.
16. Doder M., Rabiner E.A., Turjanski N., Lees A.J., Brooks D.J. Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 2003, 60(4):601-605.
17. Eskow Jaunarajs K.L., Dupre K.B., Ostock C.Y., Button T., Deak T., Bishop C. Behavioral and neurochemical effects of chronic l-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat. Behav. Pharmacol. 2010, 21(7):627-637.
18. Frechilla D., Cobreros A., Saldise L., Moratalla R., Insausti R., Luquin M., Del Río J. Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 2001, 39(4):288-296.
19. Guiard B.P., El Mansari M., Merali Z., Blier P. Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int. J. Neuropsychopharmacol. 2008, 11(5):625-639.
20. Haj-Dahmane S. D2-like dopamine receptor activation excites rat dorsal raphe 5-HT neurons in vitro. Eur. J. Neurosci. 2001, 14(1):125-134.
21. Hollister A.S., Breese G.R., Mueller R.A. Role of monoamine neural systems in l-dihydroxyphenylalanine-stimulated activity. J. Pharmacol. Exp. Ther. 1979, 208(1):37-43.
22. Jolas T., Aghajanian G.K. Opioids suppress spontaneous and NMDA-induced inhibitory postsynaptic currents in the dorsal raphe nucleus of the rat in vitro. Brain Res. 1997, 755(2):229-245.
23. Jolas T., Nestler E.J., Aghajanian G.K. Chronic morphine increases GABA tone on serotonergic neurons of the dorsal raphe nucleus: association with an up-regulation of the cyclic AMP pathway. Neuroscience 2000, 95(2):433-443.
24. Kalén P., Skagerberg G., Lindvall O. Projections from the ventral tegmental area and mesencephalic raphe to the dorsal raphe nucleus in the rat. Evidence for a minor dopaminergic component. Exp. Brain Res. 1988, 73(1):69-77.
25. Kirby L.G., Pernar L., Valentino R.J., Beck S.G. Distinguishing characteristics of serotonin and non-serotonin-containing cells in the dorsal raphe nucleus: electrophysiological and immunohistochemical studies. Neuroscience 2003, 116(3):669-683.
26. Kirik D., Georgievska B., Burger C., Winkler C., Muzyczka N., Mandel R.J., Bjorklund A. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of l-dopa using rAAV-mediated gene transfer. Proc. Natl. Acad. Sci. U.S.A. 2002, 2;99(7):4708-4713.
27. Kish S.J., Tong J., Hornykiewicz O., Rajput A., Chang L.J., Guttman M., Furukawa Y. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008, 131:120-131.
28. Kitahama K., Nagatsu I., Geffard M., Maeda T. Distribution of dopamine-immunoreactive fibers in the rat brainstem. J. Chem. Neuroanat. 2000, 18(1-2):1-9.
29. Kovacs G.G., Klöppel S., Fischer I., Dorner S., Lindeck-Pozza E., Birner P. Nucleus-specific alteration of raphe neurons in human neurodegenerative disorders. Neuroreport 2003, 14(1):73-76.
30. Lammel S., Hetzel A., Häckel O., Jones I., Liss B., Roeper J. Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. Neuron 2008, 57(5):760-773.
31. Lundblad M., Picconi B., Lindgren H., Cenci M.A. A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2004, 16(1):110-123.
32. Mackay A.V., Yates C.M., Wright A., Hamilton P., Davies P. Regional distribution of monoamines and their metabolites in the human brain. J. Neurochem. 1978, 30(4):841-848.
33. Mansour A., Meador-Woodruff J.H., Bunzow J.R., Civelli O., Akil H., Watson S.J. Localization of dopamine D2 receptor mRNA and D1 and D2 receptor binding in the rat brain and pituitary: an in situ hybridization-receptor autoradiographic analysis. J. Neurosci. 1990, 10(8):2587-2600.
34. Molina-Holgado E., Dewar K.M., Grondin L., van Gelder N.M., Reader T.A. Changes of amino acid and monoamine levels after neonatal 6-hydroxydopamine denervation in rat basal ganglia, substantia nigra, and Raphe nuclei. J. Neurosci. Res. 1993, 1;35(4):409-418.
35. Moukhles H., Bosler O., Bolam J.P., Vallée A., Umbriaco D., Geffard M., Doucet G. Quantitative and morphometric data indicate precise cellular interactions between serotonin terminals and postsynaptic targets in rat substantia nigra. Neuroscience 1997, 76(4):1159-1171.
36. Muñoz A., Li Q., Gardoni F., Marcello E., Qin C., Carlsson T., Kirik D., Di Luca M., Björklund A., Bezard E., Carta M. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia. Brain 2008, 131(Pt 12):3380-3394.
37. Navailles S., Bioulac B., Gross C., De Deurwaerdère P. Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease. Neurobiol. Dis. 2010, 38(1):136-143.
38. Navailles S., Benazzouz A., Bioulac B., Gross C., De Deurwaerdère P. High-frequency stimulation of the subthalamic nucleus and l-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease. J. Neurosci. 2010, 10;30(6):2356-2364.
39. Ng K.Y., Chase T.N., Colburn R.W., Kopin I.J. l-Dopa-induced release of cerebral monoamines. Science 1970, 170(953):76-77.
40. Ng K.Y., Colburn R.W., Kopin I.J. Effects of l-dopa on efflux of cerebral monoamines from synaptosomes. Nature 1971, 230(5292):331-332.
41. Olanow C.W., Obeso J.A., Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006, 5(8):677-687.
42. Pan Z.Z., Williams J.T., Osborne P.B. Opioid actions on single nucleus raphe magnus neurons from rat and guinea-pig in vitro. J. Physiol. 1990, 427:519-532.
43. Peyron C., Luppi P.H., Kitahama K., Fort P., Hermann D.M., Jouvet M. Origin of the dopaminergic innervation of the rat dorsal raphe nucleus. Neuroreport 1995, 116(18):2527-2531.
44. Rylander D., Parent M., O'Sullivan S.S., Dovero S., Lees A.J., Bezard E., Descarries L., Cenci M.A. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann. Neurol. 2010, 68(5):619-628.
45. Tadaiesky M.T., Dombrowski P.A., Figueiredo C.P., Cargnin-Ferreira E., Da Cunha C., Takahashi R.N. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. Neuroscience 2008, 156(4):830-840.
46. Uretsky N.J., Iversen L.L. Effects of 6-hydroxydopamine on noradrenaline-containing neurones in the rat brain. Nature 1969, 221(5180):557-559. (Feb 8).
47. Vandermaelen C.P., Aghajanian G.K. Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurons recorded extracellularly and intracellularly in rat brain slices. Brain Res. 1983, 19;289(1-2):109-119.
48. Wang S., Zhang Q.J., Liu J., Wu Z.H., Wang T., Gui Z.H., Chen L., Wang Y. Unilateral lesion of the nigrostriatal pathway induces an increase of neuronal firing of the midbrain raphe nuclei 5-HT neurons and a decrease of their response to 5-HT(1A) receptor stimulation in the rat. Neuroscience 2009, 159(2):850-861.
49. Zhang Q.J., Gao R., Liu J., Liu Y.P., Wang S. Changes in the firing activity of serotonergic neurons in the dorsal raphe nucleus in a rat model of Parkinsons disease. Sheng Li Xue Bao 2007, 59(2):183-189.